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ABSTRACT
Background
Schistosomiasis is a chronic, debilitating parasitic disease infecting more than 200 million
people and is second only to malaria in terms of public health importance. Due to the lack of a
vaccine, patient therapy is heavily reliant on chemotherapy with praziquantel as the World
Health Organization–recommended drug, but concerns over drug resistance encourage the
search for new drug leads.
Methods and Findings
The efficacy of the vinyl sulfone cysteine protease inhibitor K11777 was tested in the murine
model of schistosomiasis mansoni. Disease parameters measured were worm and egg burdens,
and organ pathology including hepato- and splenomegaly, presence of parasite egg–induced
granulomas in the liver, and levels of circulating alanine aminotransferase activity as a marker of
hepatocellular function. K11777 (25 mg/kg twice daily [BID]), administered intraperitoneally at
the time of parasite migration through the skin and lungs (days 1–14 postinfection [p.i.]),
resulted in parasitologic cure (elimination of parasite eggs) in five of seven cases and a
resolution of other disease parameters. K11777 (50 mg/kg BID), administered at the
commencement of egg-laying by mature parasites (days 30–37 p.i.), reduced worm and egg
burdens, and ameliorated organ pathology. Using protease class-specific substrates and active-
site labeling, one molecular target of K11777 was identified as the gut-associated cathepsin B1
cysteine protease, although other cysteine protease targets are not excluded. In rodents, dogs,
and primates, K11777 is nonmutagenic with satisfactory safety and pharmacokinetic profiles.
Conclusions
The significant reduction in parasite burden and pathology by this vinyl sulfone cysteine
protease inhibitor validates schistosome cysteine proteases as drug targets and offers the
potential of a new direction for chemotherapy of human schistosomiasis.
The Editors’ Summary of this article follows the references.
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Schistosomiasis, or bilharzia, is a major public health
problem in tropical and subtropical regions including sub-
Saharan Africa, South America, China, and Southeast Asia.
An estimated 200 million people are infected, and a total of
400 million are at risk. Caused by blood ﬂukes of the genus
Schistosoma, the disease is associated with a chronic and
debilitating morbidity manifested by sequelae such as
cognitive impairment, lassitude, and growth stunting [1].
Disease pathology is primarily due to an immune-mediated
granulomatous response to parasite eggs trapped in the liver,
spleen, and other peritoneal organs [2]. The World Health
Organization recommends a strategy of disease control such
that the consequences of chronic infection are reduced and
maintained at a level that is no longer considered a public
health burden [1].
Up to 1975, chemotherapy of schistosomiasis had relied on
the use of antimonials and a variety of other drugs targeting
DNA synthesis, and carbohydrate and protein metabolism [3].
Since then, three drugs have been used for treatment:
metrifonate, oxamniquine, and praziquantel (PZQ); however,
it is the latter that is now universally employed, as
recommended by the World Health Organization for either
individual or mass treatment [4]. PZQ is effective against all
ﬁve species of schistosomes infecting humans: S. mansoni, S.
haematobium, S. japonicum, S. intercalatum, and S. mekongi.
Juvenile parasites (between 7 and 28 days-old), however, are
less susceptible to PZQ than adults ([5,6] and references
therein), so individuals continuously exposed to new in-
fections must be retreated. PZQ is well tolerated, easily
administered in tablet form, and inexpensive, at around
US$0.30–0.60 per 600 mg dose [1,7].
Despite the success of PZQ, the prospect of relying on a
single drug to treat 200 million people is of concern [8] and
the potential for drug resistance, particularly in areas of high
transmission, must be considered. Suspicions were raised that
low cure rates for PZQ in a schistosomiasis mansoni outbreak
in Senegal in the early 1990s were partly due to drug
resistance, although alternative interpretations discussed
included the high pretreatment levels of infection and
intense disease transmission that resulted in individuals
harboring large numbers of immature parasites inherently
less sensitive to the drug [9]. In another study, resistant
isolates of S. mansoni had been obtained from patients
multiply treated with PZQ in the Nile Delta. These parasites
showed 2- to 6-fold elevated ED50 (the dose required to kill
50% of parasites) values compared to isolates not previously
exposed to PZQ [10]. Finally, resistance to PZQ has been
selected for in laboratory mice [11]. Whether or not the
identiﬁed or suspected resistance turns out to be clinically
relevant, there are sufﬁcient grounds for both continued
vigilance and the development of alternative chemotherapies.
One encouraging approach to novel antiparasitic agents is
the development of small-molecule inhibitors of cysteine
proteases (CPs) [12]. CPs are fundamental to the metabolism
of many parasites [13], and CP inhibitors have been shown to
kill protozoan parasites in both culture [14,15] and animal
models of disease [16,17]. Schistosomes also express a number
of CPs that function in digestion, reproduction, and protein
turnover [18], and it has been shown that ﬂuoromethyl
ketone-based CP inhibitors decrease worm and egg burdens
in mice infected with S. mansoni [19]. Since these studies were
published, signiﬁcant advances—such as improved solubility
and bioavailability, and reduced toxicity—have been incor-
porated into the design of new-generation CP inhibitors. One
such inhibitor, N-methyl-piperazine-phenylalanyl-homophe-
nylalanyl-vinylsulfone phenyl (K11777), is a well-tolerated,
orally bioavailable compound currently in the late stages of
preclinical development for Chagas’ disease (caused by
infection with a protozoan parasite, Trypanosoma cruzi)
[20,21]. For this report, we assessed the efﬁcacy of K11777-
treatment in mice infected with S. mansoni by measuring
worm and egg burdens, and liver and spleen pathologies.
Also, identiﬁcation of the protease target(s) of K11777 in the
parasite was sought.
Methods
Maintenance of the S. mansoni Life Cycle
A Puerto Rican isolate of S. mansoni was maintained in the
laboratory using Biomphalaria glabrata snails and mice as
intermediate and deﬁnitive hosts, respectively [22]. BALB/C
mice (aged 5–6 wk) were purchased from Charles River (http://
www.criver.com) and maintained at the Animal Care Facility,
Veterans Affairs Medical Center (VAMC) San Francisco in
accordance with protocols approved by the VAMC Institu-
tional Animal Care and Use Committee. Infections of mice
with S. mansoni were initiated by subcutaneous injection of 150
cercariae (infective larvae). At 49 d postinfection (p.i.), mice
were euthanized with an intraperitoneal (i.p.) injection of 0.05
mg/g sodium pentobarbital, and adult worms were perfused
[23] in RPMI 1640 medium (Invitrogen, http://www.invitrogen.
com) containing 10% bovine calf serum (Invitrogen).
Drug Treatment
K11777 was dissolved in sterile distilled water at a
concentration of 5 or 10 mg/ml and administered in 100 ll
by i.p. injections twice daily (BID) according to the schedules
indicated in Figure 1. Infected control mice were adminis-
Figure 1. Experimental Design for Assessing the Therapeutic Effect of
the Cysteine Protease Inhibitor K11777 on Mice Infected with S. mansoni
A l lm i c ew e r ei n f e c t e dw i t h1 5 0S. mansoni cercariae injected
subcutaneously. K11777 was administered intraperitoneally in 100 llo f
water at the dosages and timings indicated. Control mice received water
alone. All mice were perfused at 49 days p.i., and worm and egg burdens
and organ pathology were assessed.
doi:10.1371/journal.pmed.0040014.g001
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experiment, two early and two late drug treatments were
conducted with ﬁve mice per experiment.
Measurement of Total Worm Burden, Hepatic Egg Burden,
and Organ Weights
Numbers of male and female worms obtained by perfusion
were recorded, as were the weights of livers and spleens. For
determination of parasite egg burdens, livers from infected
animals were digested in 0.7% porcine trypsin in PBS for 1 h
at 37 8C on an orbital shaker. Eggs were then sedimented at 4
8C and counted under a dissecting microscope as described
previously [24].
Measurement of Hepatic Pathology
As a quantitative indicator of hepatocellular damage,
circulating levels of alanine aminotransferase (ALT) were
measured. Heparinized blood samples were obtained by
cardiac puncture at the time of euthanasia and ALT activity
measured in a Beckman Chemical Analyzer. Baseline plasma
ALT levels were also determined for age-matched uninfected
animals. For histopathology, a piece of one liver lobe was
removed and ﬁxed in 4% PBS-buffered formaldehyde. The
tissue was parafﬁn embedded, sectioned at 5 lm, and
processed for hematoxylin and eosin staining using standard
protocols.
Measurement of S. mansoni Cysteine Protease Activity
Upon perfusion, worms were washed ﬁve times in RPMI-
1640 without serum and frozen at  80 8C. Soluble worm
extracts were prepared and endogenous CP activity measured
essentially as previously described [25] using benzyloxycar-
bonyl-phenylalanyl-arginyl-7-amido-4-methylcoumarin (Z-
Phe-Arg-AMC; Bachem, http://www.bachem.com) and Z-Arg-
Arg-AMC as substrates for cathepsins B and L, and cathepsin
B, respectively. Reaction of worm extracts with the radio-
labeled CP inhibitor
125I-DCG-04 was carried out as pre-
viously described [26]. Prior to labeling, some samples were
preincubated for 1 h with the selective cathepsin B inhibitor
CA-074 [27] at a ﬁnal concentration of 5 lM. All samples were
heated to 70 8C for 10 min in 13NuPAGE LDS sample buffer
(Invitrogen) containing 50 mM DTT, and were subjected to
SDS-PAGE through 4%–20% gradient gels. Labeled proteins
were visualized by autoradiography using standard method-
ologies.
Statistics
The data from each early or late experiment were
combined for presentation and statistical analysis. Data were
plotted as individual points and included median values. All
data were subjected to the Mann-Whitney nonparametric test
to determine any statistical differences in egg and worm
burdens, and organ pathologies between treated and un-
treated control mice.
Results
K11777 Significantly Decreases S. mansoni Egg and Worm
Burdens, and Hepatosplenomegaly
An initial range-ﬁnding experiment (‘‘long course,’’ Figure
1) was begun on day 7 p.i. and continued for 35 d with i.p.
injections of K11777 at 25 mg/kg BID. By day 7 p.i., immature
schistosomula (larvae) have left the skin invasion site, attained
the venous system, and are in transit through the lung
capillaries before ﬁnally settling in the hepatic portal venous
system. The length of time required for this migration
depends on the species of schistosome, but for S. mansoni it
is nominally 14 d [28,29]. By day 49 p.i., at the time of worm
recovery, male and female worms have matured and paired,
and eggs are found in the liver, intestine, and feces [30].
As shown in Figure 2A, K11777 dramatically decreased (by
92%) the total number of eggs recovered in livers of treated
mice (median of 1,538 eggs/liver; n ¼ 5) compared to
untreated controls (median of 20,210 eggs/liver; n ¼ 5). Egg
production is contingent on worm maturation, pairing of
males and females, and the support of the metabolic needs of
Figure 2. Long-Course Treatment with K11777 Dramatically Decreases
Egg and Worm Burdens in Mice Infected with S. mansoni
Results from the experiment outlined in Figure 1 are shown for egg (A)
and worm (B) burdens. Points represent data from individual treated or
untreated (control) infected mice. The horizontal bars represent median
values: *p ¼ 0.03; **p ¼ 0.008.
doi:10.1371/journal.pmed.0040014.g002
PLoS Medicine | www.plosmedicine.org January 2007 | Volume 4 | Issue 1 | e14 0132
Novel Treatment of Schistosomiasisthe female. K11777 clearly disrupted this developmental
process by directly killing worms: female and male burdens
were reduced by 80% and 79%, respectively (Figure 2B).
Furthermore, those surviving worms exposed to K11777 were
clearly smaller in both girth and length (Figure 3).
The pathology of chronic schistosomiasis is due to a
granulomatous inﬂammation in response to eggs that are
trapped in host tissues, particularly the liver and spleen in the
case of S. mansoni [2]. As a consequence, gross hepato- and
splenomegaly become obvious in infected animals, and
punctate ﬁbrotic foci are visible on the surface of the liver
after necropsy. With treated mice, few ﬁbrotic lesions were
visible on the liver (unpublished data), and spleen and liver
weights were decreased by 54% and 29%, respectively,
compared to untreated controls (Figure 4).
Treatment with K11777 Targets S. mansoni Cathepsin B1
To determine the molecular target(s) of K11777, extracts
were prepared from worms surviving the long-course treat-
ment and processed for endogenous proteolytic activity.
Substantially less CP activity (per microgram of protein) was
measured in these extracts compared to those of control
worms (Figure 5A). Activity against the selective cathepsin B
substrate Z-Arg-Arg-AMC, or the substrate for cathepsins B
and L Z-Phe-Arg-AMC, was decreased by approximately 90%.
Upon incubation of control untreated worm extracts with the
speciﬁc CP active site ‘‘tag,’’
125I-DCG-04, a major protease
species at 31 kDa was labeled after resolution by SDS-PAGE
(Figure 5B, lane 2). By contrast, using the same protein
concentration of worms exposed to K11777, active site
labeling was decreased by approximately 10-fold (by scanning
densitometry; Figure 5B, lane 4). For extracts of both control
and drug-exposed worms, labeling with
125I-DCG-04 could be
inhibited by prior incubation with the cathepsin B-selective
inhibitor CA-074 (Figure 5B, lanes 1 and 3, respectively),
conﬁrming the 31 kDa reactive species as the gut-associated
cathepsin B1, in accordance with previous data [31]. The
second and faster migrating protease species in lane 1 is
consistent with a schistosome cathepsin L [31].
‘‘Early’’ Treatment with K11777 Eliminates Egg Production
and Severely Impacts Worm Burden
A second treatment, termed ‘‘early’’ and designed to
coincide directly with the skin and lung migratory phases of
the parasite (Figure 1), was started at day 1 p.i. and continued
for 14 d with 25 mg/kg BID. This drug regimen resulted in
parasitologic cure (elimination of egg production) in ﬁve of
the seven mice tested (Figure 6A). The remaining two mice
each produced just 454 and 159 eggs/liver. By contrast, livers
from untreated control mice (n ¼ 10) had a median value of
13,376 eggs/liver. The same drug regimen dramatically
reduced female and male worm survival by 90% and 88%,
respectively, and in the ﬁve mice without parasite eggs in the
liver, no female worms were recovered (Figure 6B). As found
for the long-course drug regimen, the few worms surviving
treatment were considerably smaller (unpublished data).
Early Treatment with K11777 Resolves Pathology in the
Liver and Spleen
Early treatment with K11777 decreased spleno- and
hepatomegalies by 68% and 33%, respectively, relative to
the untreated controls (Figure 7). For both organs, weights
were similar to those from age-matched uninfected mice (n¼
4). Liver function in treated animals, as judged by median
plasma levels of ALT, was close to that of uninfected mice (38
versus 21 IU/l), whereas the ALT level in untreated control
mice was approximately four times higher (152 IU/l; Figure
8). Gross evidence of ﬁbrotic foci on the liver surface at
necropsy was absent in treated mice (unpublished data), and
this resolution in pathology associated with parasite eggs was
conﬁrmed by light microscopy. Indeed, the very low egg
burdens of 454 and 159 eggs/liver in two of the seven livers of
treated mice made difﬁcult the identiﬁcation of any
granulomas. By contrast, many large granulomas were found
in liver sections from untreated controls (Figure 9B), each
consisting of a dense cellular inﬁltrate that included macro-
phages, eosinophils, and lymphocytes.
Figure 3. Long-Course Treatment with K11777 of Mice Infected with S.
mansoni Retards Worm Growth
Representative worms treated with K11777 in the experiment outlined in
Figure 1 are shown.
doi:10.1371/journal.pmed.0040014.g003
Figure 4. Long-Course Treatment with K11777 Resolves Egg-Induced
Hepato- and Splenomegalies in S. mansoni–Infected Mice
Points represent data from individual mice that were infected and
treated, infected and untreated (control), or uninfected (Figure 1). The
horizontal bars represent median values:
**p ¼ 0.007. The hatched lines
represent the baseline for age-matched uninfected mice.
doi:10.1371/journal.pmed.0040014.g004
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Production and Worm Burden
By 30 days p.i., worms have matured, paired and com-
menced egg-production in the portal system of the host.
Accordingly, a ‘‘late’’ treatment was initiated to coincide with
this life-cycle phase (Figure 1). K11777 at 50 mg/kg BID for 8 d
decreased egg burdens by 81 % (median of 2,545 eggs/liver; n
¼ 7) compared to untreated controls (Figure 6A). With
respect to worm burdens (Figure 6B), the 54 % reduction in
the median value for females was not signiﬁcantly different
from the untreated control group (p ¼ 0.2), whereas the 57%
reduction for male worms was (p ¼ 0.0007). As with the two
previous drug treatments, worms exposed to K11777 were
noticeably smaller (unpublished data).
Late Treatment with K11777 Decreases Liver and Spleen
Pathology
Median spleen and liver weights of treated mice were
decreased by 46% and 23%, respectively, compared to
untreated controls (Figure 7). Also, ﬁbrotic foci on the
surface of the livers were less numerous (unpublished data).
However, liver function, as measured by assay of plasma ALT
(median of 150 IU/l), was not improved over that of untreated
control mice (p ¼ 0.9; Figure 8). By light microscopy, egg-
associated granulomas in treated mice were poorly developed
(Figure 9A) compared to the extensive granulomatous
reaction surrounding parasite eggs in livers from untreated
control mice (Figure 9B).
Discussion
In this study we have demonstrated that K11777 is a potent
schistosomicide that achieves parasitologic cure (absence of
eggs) and retards egg-associated organ pathology when given
early in infection or signiﬁcantly decreases egg burden and
organ pathology when given late in infection. Furthermore,
using CP-speciﬁc substrates and active site labeling, we
identiﬁed one molecular target of K11777 as the major CP
associated with the schistosome gut, cathepsin B1.
PZQ is the recommended drug for treatment of schistoso-
miasis; however, concerns about reliance on a single drug to
treat 200 million people, and the potential for drug
resistance, make identiﬁcation of alternative schistosomiasis
chemotherapies a high priority. Over the last ten years, an
intensive medicinal chemistry effort has concentrated on the
design of small-molecule inhibitors of CPs as novel antipar-
asitic agents, including against falciparum malaria [14],
Chagas’ disease (T. cruzi [16]) and African sleeping sickness
(T. brucei [17]). The molecular targets are the Clan CA (papain-
like) CPs that are ubiquitous in parasitic protozoa [13] and
helminths [18,32].
Previously developed CP inhibitor scaffolds using dipep-
tidyl diazo- and ﬂuoromethyl ketones had antitrypanosomal
[17] and antischistosomal [19] activities. However, concerns
about diazo teratogenicity [33] and ﬂuoride toxicity [34]
dissuaded their continued development. Further medicinal
chemistry exploration identiﬁed the peptidomimetic vinyl
sulfones like K11777 as improved inhibitor leads because they
are nontoxic, relatively unreactive with glutathione, and
stable in water [35].
K11777 has undergone extensive pharmacokinetic [21,36]
and toxicological screening as a potential therapy for Chagas’
Figure 5. A Principal Molecular Target of K11777 in S. mansoni is the
Cathepsin B1 Cysteine Protease
(A) Extracts of worms exposed to long-course treatment with K11777
(see Figure 1) had significantly less protease activity (relative fluores-
cence units/min/lg of extract) against the cathepsin B–selective
substrate Z-Arg-Arg-AMC (Z-RR-AMC) or the cathepsins B- and L-specific
substrate Z-Phe-Arg-AMC (Z-FR-AMC).
(B) By SDS-PAGE, a major 31 kDa protease species in extracts of control
worms (lane 2) or worms exposed to K11777 (lane 4) reacted with the
radiolabeled CP inhibitor
125I-DCG-04. The reaction was approximately
10-fold less intense in the latter by scanning densitometry. For both
extracts, the reaction with
125I-DCG-04 could be inhibited by prior
incubation with the cathepsin B–selective inhibitor CA-074 (lanes 1 and
3), thus confirming the 31 kDa reactive species as cathepsin B1 [31]. The
second, faster-migrating protease species in lane 1 is consistent with a
schistosome cathepsin L [31].
doi:10.1371/journal.pmed.0040014.g005
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(20%), and, at the highest therapeutic dose of 50 mg/kg BID
used here, neither toxic nor mutagenic (Table 1). At the same
dosage, K11777 cures T. cruzi infection in mice via inhibition
of the CP cruzain [16]. The compound originated from an
industrial medicinal chemistry program to produce inhib-
itors of human cathepsins for use in vivo [37,38], and one
concern about its use as an antiparasitic is its potential to
inhibit host orthologous proteases. Although K11777 is
indeed a potent inhibitor of human cathepsin S in vitro,
evidence that it could signiﬁcantly decrease host protease
activity in vivo was not found (J. Palmer, personal commu-
nication). Also, for practical purposes, only short-course
disease therapies are envisaged, and both the present
compound (Table 1, see also [16]) and other vinyl sulfones
[39], demonstrate satisfactory toxicological proﬁles in this
setting.
With respect to Schistosoma, juvenile and adult worms
express a number of Clan CA proteases, including cathepsins
B1, F, and L [18,31,32], which, in the parasite gut, operate
synergistically and with some functional redundancy to
degrade host proteins as a source of nutrition [40]. As yet,
the issue of whether any one molecule represents an
appropriate drug target is unclear [18] and given the lack of
selectivity of K11777 for any single Clan CA protease [37], it is
quite possible that our data arise from the inhibition of more
than one schistosome protease target. Nonetheless, it is clear
that K11777 demonstrates signiﬁcant schistosomicidal activ-
ity, including parasitologic cure, and that one molecular
target of the compound is the major gut-associated cathepsin
B1 [18,25,31].
An initial range-ﬁnding drug trial (‘‘long-course,’’ starting
at day 7 p.i. for 35 d [Figure 1]) established K11777 as a potent
schistosomicide by dramatically reducing both egg and worm
burdens. Also, those worms surviving treatment were notice-
ably smaller. In addition, the pathology normally associated
with the deposition of schistosome eggs in the spleen and
liver was clearly ameliorated. Finally, when extracts of
surviving worms were tested for CP activity using selective
substrates and active site labeling, K11777 had knocked down
the activity of the major gut-associated protease, cathepsin B1
[31]. The identiﬁcation of schistosome cathepsin B1 as a
molecular target of K11777 is consistent with its central
nutritive function in the digestion of host blood proteins
[18,40] and RNA interference of its expression, although not
lethal to cultured parasites [41,42], is nonetheless detrimental
to worm growth and development [41].
Early treatment with K11777 effectively cured ﬁve of the
seven mice treated—no eggs were found in the respective
Figure 6. Early and Late Treatment of Mice with K11777 Significantly
Decreases Egg and Worm Burdens in Mice Infected with S. mansoni
Results for egg (A) and worm (B) burdens following the experimental
protocol depicted in Figure 1 are shown. Points represent data from
individual mice which were combined from either two early or two late
treatment experiments. The horizontal bars represent median values: **p
¼ 0.002, *** p ¼ 0.0007. The data comparing female worm burdens
between late treatment and untreated controls were not statistically
different (p ¼ 0.2).
doi:10.1371/journal.pmed.0040014.g006
Figure 7. Early and Late Treatment of Mice with K11777 Decreases
Hepato- and Splenomegalies in Mice Infected with S. mansoni
Points represent data from individual mice which were combined from
either two early or two late treatment experiments (see Figure 1). The
horizontal bars represent median values: * p ¼ 0.02, ** p ¼ 0.004, ***p ¼
0.0003. The hatched lines represent the baseline for age-matched
uninfected mice.
doi:10.1371/journal.pmed.0040014.g007
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remaining two mice, egg production was negligible. Com-
mensurate with these ﬁndings, spleen and liver pathologies,
pronounced in untreated infected control mice, were not
evident, and plasma ALT levels indicating liver function were
close to normal. The signiﬁcant amelioration of disease
parameters upon early treatment was more dramatic than
that seen with either the long course or the late treatments.
This difference suggests that young parasites migrating
through the skin and lungs are particularly sensitive to
exogenous inhibitors, an observation that is consistent with
previous studies of ﬂuoromethyl ketone CP inhibitors [19].
Such effects on immature worms are drug speciﬁc, however.
PZQ, for example, is effective against very young (aged ,1
wk) invasive parasites in mice, but loses efﬁcacy during the
lung-migratory period and maturation of the parasites up to
approximately 28 days p.i., at which time the drug regains
potent bioactivity [5,6]. In contrast, the artemisinin deriva-
tives (artemether and artesunate), which are being evaluated
in combination with PZQ for therapy of schistosomiasis
[6,43], are most active against the juvenile migratory stages
and progressively lose bioactivity as parasites mature [6,44].
The greater sensitivity of young migratory S. mansoni to
K11777 can be rationalized in terms of their containing less
CP activity than older, larger worms that have reached the
hepatic portal system. This hypothesis is supported by data
reported from a study of larval parasites exposed to RNA
interference targeting cathepsin B1 and subsequently in-
jected into mice. Worms recovered 21 days later were
markedly smaller than their counterparts exposed to off-
target RNA interference [41]. It is only upon reaching the
hepatic portal vessels (between days 8 and 14 p.i.) that cell
division, blood feeding, and weight gain accelerate dramat-
ically [28], and this elevated metabolism is positively
correlated with increased speciﬁc CP activity [45]. Likewise,
the greater sensitivity of male worms to K11777 in the late
drug regimen can be explained by their containing less
protease activity than females [46,47]. Females must ingest
and degrade far greater amounts of blood proteins [48] in
order to sustain the large-scale egg production characteristic
of chronic schistosome infection.
An early treatment protocol would be ideal in cases where
early diagnosis can be made, such as in tourists, aid workers,
and military personnel. However, in endemic areas, most
patients have established infections with mature egg-laying
worms and concomitant hepatic complications. The late
treatment protocol, begun at 30 days p.i. when worms have
paired and commenced egg production [28,30], had a less
Figure 8. Early Treatment of S. mansoni–Infected Mice with K11777
Retards Hepatocellular Damage Arising from Parasite Eggs
Plasma samples from mice in experiments outlined in Figure 1 were
quantitatively assayed for the presence of ALT activity as a marker for
hepatocellular damage. Points represent data from individual mice which
were combined from either two early or late treatment experiments. The
horizontal bars represent median values; ***p ¼ 0.002. For plasma from
late-treatment mice, ALT activity was not significantly different (p ¼ 0.9)
from untreated controls, most likely due to the re-emergence of
hepatocellular toxicity upon cessation of treatment at day 37 p.i.—i.e.,
12 days prior to the end of the experiment and recovery of worms. The
hatched line represents the baseline for age-matched uninfected mice.
doi:10.1371/journal.pmed.0040014.g008
Figure 9. Late Treatment of S. mansoni–Infected Mice with K11777 Decreases the Granulomatous Reaction to Parasite Eggs Trapped in the Liver
After necropsy of mice from experiments outlined in Figure 1, livers were sectioned at 5 lm and stained with hematoxylin and eosin. Arrows in
representative sections indicate schistosome eggs; the granulomatous reaction to the eggs is much reduced after the late-treatment regimen (A),
compared to the intense reaction visible in sections from untreated control mice (B). Note that after early K11777 treatment, eggs or egg-associated
granulomas were not found (unpublished data). Scale bar ¼ 100 lm.
doi:10.1371/journal.pmed.0040014.g009
PLoS Medicine | www.plosmedicine.org January 2007 | Volume 4 | Issue 1 | e14 0136
Novel Treatment of Schistosomiasisdramatic effect on disease parameters compared to early
drug treatment. Nonetheless, a striking decrease in egg and
male worm burdens, smaller egg-associated granulomas, and
decreased gross organ pathology were recorded. This is
encouraging, both for preventing or retarding morbidity
associated with the disease and for decreasing environmental
contamination by schistosome eggs, and, thus, the level of
disease transmission [1].
Because K11777 is in the late stages of preclinical develop-
ment for treatment of Chagas’ disease [20,21], it may be
available for parallel clinical trials against schistosomiasis in
the relatively near future. One intriguing possibility for its
use would be in combination with PZQ (similar to that which
has been proposed for derivatives of artemisinin), as the two
compounds have very different mechanisms of action and
could conceivably operate synergistically, as well as minimize
the possibility of drug resistance.
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Editors’ Summary
Background. Schistosomiasis, a disease caused by a type of parasitic
flatworm that lives in the blood, infects around 200 million people
worldwide. The disease is a serious problem in sub-Saharan Africa, South
America, China, and southeast Asia. Although this disease can kill, it is
better known as a lifelong chronic infection with debilitating symptoms
mainly due to an immune reaction raised against parasite eggs trapped
in the liver, spleen, and gut. The worm’s life cycle is complicated and
involves a free-swimming form that emerges from certain types of snails
that live in lakes and ponds. This can penetrate the skin of people in
contact with the water. After a period spent in the skin and around the
lungs, the parasites move to veins around the gut, and develop into
adult worms that mate and lay eggs. These eggs eventually return to the
water through the person’s feces or urine. A particular group of proteins
called cysteine proteases are thought to be very important in the biology
of these worms, especially in their function as digestive enzymes in the
parasite’s gut. These proteases could represent an exciting opportunity
for development of new drugs to treat schistosomiasis. The researchers
are looking at whether it is possible to block the activity of cysteine
proteases and, as a result, kill the worms or prevent them from
developing and thriving.
Why Was This Study Done? At the moment there is only one drug,
praziquantel, in common use for treatment of schistosomiasis; it is cheap
and effective. However many organizations are worried about relying on
a single drug to treat a serious disease which affects so many people
worldwide. The research group here has been looking at molecules that
block cysteine protease activity, to see if any of these could be good
drug candidates for schistosomiasis. One molecule they have been
looking at goes by the name of K11777, which is under evaluation as a
drug candidate for another parasitic infection (Chagas’ disease). Here, the
researchers wanted to find out whether K11777 had any activity against
schistosome worms.
What Did the Researchers Do and Find? In this study, the researchers
deliberately infected laboratory mice with the schistosome parasite.
These mice were then either injected with K11777 solution twice daily, or
with equivalent volumes of water as a comparison. The researchers
examined the effects of injecting K11777 either ‘‘early’’ in infection
(using a 14 day course, starting 1 day after infection with the parasite) or
‘‘late’’ in the worms’ development (using an 8 day treatment course
starting 30 days after infection). The outcomes used as measures of
success of treatment with K11777 included the number of worms
recovered from mice after euthanasia, the number of worm eggs
counted in the liver; the extent of the damage to the liver; and finally, the
researchers also looked at activity levels of cysteine proteases in the
worms themselves, in particular, those proteases associated with the
parasite gut.
The results of the early-treatment experiment showed a substantial
decrease in worm numbers and egg production. In five of the seven mice
treated, eggs were eliminated entirely. Also, there was little measurable
liver damage. For the late-treatment experiment, decreased burdens of
worms and eggs in the livers of K11777 treated mice were also found,
and there was less damage to the livers. Those worms surviving
treatment and removed from mice also had much less activity of gut
cysteine proteases suggesting that K11777 exerts its effects by targeting
worm cysteine proteases.
What Do These Findings Mean? These experiments show that K11777
is a potent antischistosomal agent in mice. It might therefore be a good
‘candidate’ molecule for developing future treatments for human
schistosomiasis. However, before that stage can be reached, it would
be important to carry out clinical trials to test whether K11777 is both
safe and effective in schistosomiasis patients. Full details as to which
worm cysteine protease(s) is the critical target of K11777 would also
need to be worked out, and more information would be needed as to
whether the dosing plan used in this study (twice-daily injections for a
week to 14 days) can be decreased.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040014.
  World Health Organization pages about schistosomiasis including links
to details on further research into the disease
  Information from the US Centers for Disease Control for patients and
health professionals about schistosomiasis
  Wikipedia pages on schistosomiasis (Wikipedia is an internet
encyclopedia anyone can edit)
  PLoS Neglected Tropical Diseases is a new journal from the Public
Library of Science that is devoted to publishing research on the
world’s most neglected tropical diseases, including schistosomiasis
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